Contact Sales
.
banner
Whitepaper
Whitepaper

Overcoming three key pharma compliance challenges in 2025

Pharmaceutical manufacturers whose products are participating in government drug pricing programs must navigate an ever-evolving legislative landscape to strike a balance between risk and value. In 2025, manufacturers are entering a new era in which compliance is less about following mandated protocols and more about mitigating government program liability. Unlike simply altering their assumptions to deal with these changes, pharma companies are now faced with overhauling their models to adjust to many net-new challenges.

This white paper covers:

  • The latest developments in three key compliance challenges that will continue to impact pharma companies this year – the Inflation Reduction Act (IRA), the 340B Drug Pricing Program, and state drug price transparency laws.
  • How some U.S. manufacturers are pushing back on regulatory demands.
  • Expert insight for staying compliant and protecting revenue in this dynamic landscape.
whitepaper
whitepaper
whitepaper
2025 State of Revenue Report
The 7th annual State of Revenue Report reveals the power of data and analytics in optimizing life sciences and high-tech revenue. VIEW whitepaper
webinar
webinar
webinar
The Future of Regulatory Compliance: What to Watch for in 2025
This webinar will bring together leading experts from across the industry to explore the latest regulatory trends shaping the future of compliance. VIEW webinar
Hands of chemist in a pharmacy checking medicine on a laptop at a dispensary. Closeup of a pharmacist filling a prescription, or checking information online for medication inside a drugstore
video
video
video
Formulary Compliance
Ineffective formulary validations restrict patient access to medications and cost manufacturers millions of dollars. VIEW video